Introduction

The obesity rate has tripled since 1975, and over 650 million adults were obese in 2016 [1]. Obesity is an overwhelming yet relatively neglected health problem [2]. In the United Kingdom overweight and obesity were the underlying causes of 11% of colorectal cancer (CRC) [3].

Minimally invasive colorectal cancer procedures (MICCP) are gaining popularity. The rise in the rates of cancer, obesity and minimally invasive surgery will increase the demand for elective MICCP. Yet, although this approach is attracting many surgeons, it carries an array of challenges in individuals with obesity.

A multimodal approach to manage this multifactorial problem is imperative; moreover, it should begin early in the patient’s therapeutic journey. This article highlights solutions to overcome some of the technical challenges seen in MICCP. Bariatric and colorectal surgeons in our center collaborated in an attempt to improve the surgical outcome in obese patients undergoing elective CRC procedures, with special attention to elective MICCP (Table 1).

Perioperative considerations

Standardization of care

The standard enhanced recovery after surgery adopted by colorectal surgeons lacks specifications for patients with obesity. A perioperative pathway for obese patients (PPOP) has proven to reduce adverse events. Boodaie et al. showed significant reduction in the return-to-theatre unplanned readmissions rates and length of hospital stay. They have also shown that utilization of a morbid obesity-specific antibiotic protocol, which avoids underdosing, reduces the rate of superficial and deep infections. Such protocols may also reduce operating time by avoiding delays through standardising equipment and instruments [4]. In theory, PPOPs will help produce tailored chemotherapy and venous thromboembolism (VTE) prophylaxis protocols. They may also allow the introduction of bariatric CRC multidisciplinary meetings and the concept of intraoperative collaboration between bariatric and colorectal surgeons.

Waiting time

A longer waiting time from diagnosis to surgery has no effect on disease-specific survival in colon cancer. On the contrary, preoperative optimization reduces postoperative complications, along with length of stay, and mortality [5]. Preoperative optimization in patients with obesity might include applying concepts such as preoperative weight reduction (POWR). A delay in waiting time was associated with a drop in overall survival in rectal cancer, hence the above cannot be recommended in obese patients with rectal cancer.
## Table 1 Summary of recommendations

| Type of cancer/stage | BMI | Peri operative | Preoperative | Intraoperative | Post-operative | Surveillance |
|----------------------|-----|----------------|--------------|----------------|----------------|--------------|
|                      |     | MIS recommended | Waiting restriction | Nutrition assessment | VLCD | VLCD duration | VLCD Type | Risk prediction scores | Optical trocar/ICG/Long instruments/bariatric theatre standards and tables | Revise dosing regimen for all drugs | OSA and HDU considerations |
| Colon               |     |                |              |                |            |              |            |                          |                                |                              |              |
| Stage I              | ≥ 30 k/m² | Yes  | Yes  | No | CT body composition | If no sarcopenia | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Stage II             | ≥ 30 k/m² | Not in T4 | Yes  | No | CT body composition | If no sarcopenia | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Stage III            | ≥ 30 k/m² | Not in T4 | Yes  | No | CT body composition | If no sarcopenia | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Stage IV             | ≥ 30 k/m² | Not in T4 | Yes if operable? | No if operable | CT body composition | If no sarcopenia | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Rectum              |     |                |              |                |            |              |            |                          |                                |                              |              |
| Stage I              | ≥ 30 k/m² | No unless experienced in Lap. TME or high-risk tumours (i.e., positive margin) | Yes  | Yes | CT body composition | If no sarcopenia | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
Table 1 (continued)

| Type of cancer/stage | BMI ≥ 30 k/m² | Peri operative | Preoperative | Intraoperative | Post-operative |
|----------------------|---------------|----------------|--------------|----------------|----------------|
|                      |               | MIS recommended | Waiting restriction | Nutrition assessment | VLCD | VLCD duration | VLCD Type | Risk prediction scores | Optical trocar/ICG/Long instruments/bariatric theatre standards and tables | Revise dosing regimen for all drugs | OSA and HDU considerations | Surveillance |
| Stage II ≥ 30 k/m²   | No unless experienced in Lap. TME or high-risk tumours (i.e., positive margin) | Include in clinical pathway | Yes | Yes | CT body composition | If no sarcopenia ± in open | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Stage III ≥ 30 k/m²  | Not in T4 No unless experienced in Lap. TME or high-risk tumours (i.e., positive margin) | Yes | Yes | CT body composition | If no sarcopenia ± in open | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |
| Stage IV ≥ 30 k/m²   | Not T4? If respectable lung and/or liver metastasis post chemoradiotherapy | Yes If operable | Yes if operable | CT body composition | If no sarcopenia ± in open | 1–2 weeks | Yes | Yes | Yes | Yes | Yes |

MIS minimally invasive surgery, TME total mesorectal excision, CT computed tomography, VLCD very low calorie diet
Nutritional assessment and preoperative weight reduction

There is a misconception that all patients with obesity are well nourished. The truth is, a proportion of these patients suffer from sarcopenia [6]. None of the malnourishment screening tools used in oncology can accurately assess sarcopenia or myosteatosis. Recent innovations such as Body Composition Computed Tomography Assessment (BCCTA) can fill in this gap [7]. Determining the nutritional status is critical to determine if these patients are candidates for POWR.

When malnutrition is ruled out, preoperative diet (e.g., very low calorie diet), pharmacotherapy (e.g., liraglutide) or both can result in significant drop in the body mass index before surgery [8]. In MICCP reducing the adiposity of the mesentery and downsizing the liver can enhance the visibility and increase the intraabdominal space, thus allowing safer identification and dissection of critical structures and vessels. The exposure gained from a shrunken liver helps with colonic mobilization too. Furthermore, free intraabdominal volume increases, thus allowing better small bowel displacement cranially when needed. This may reduce the need for a steep head down position.

Preoperative case and surgeon selection

The degree of operative difficulty is variable across patients with obesity. Male gender, central obesity, hepatomegaly, fatty liver, and super-obesity are clinical predictors of complex laparoscopic surgery. The learning curve should always be addressed, thus, risk prediction scores can be used to limit difficulties related to surgeons’ inexperience, in a case-difficulty/patient-experience matching fashion.

Intraoperative considerations

Primary trocar entry can be challenging, therefore optical trocars are widely used by bariatric surgeons and could be adopted by colorectal surgeons. In MICCP, suboptimal dissection, mobilisation and vessel ligation may lead to prolonged operating times, poor resection or conversion to open. Indocyanine green (ICG) enhanced fluorescence is an evolving technology, with a relatively low cost and excellent safety profile. In MICCP, it has been used to assist in vessels’ and ureters’ identification by injecting ICG intravenously and in the bladder, respectively. This real-time angiography can help overcome the problem of vascular recognition in the heavy mesentery. Furthermore, better ureteric identification should reduce the risk of iatrogenic injury. ICG can also facilitate peritumoral lymphatic mapping in CRC. Optimizing laparoscopic ergonomics using long instruments is almost always necessary in patients with obesity. Maintaining proper manipulation and elevation angles (45°–75°, and 60°, respectively) may reduce surgeons’ exhaustion, which may require using a standing stool in some cases [9].

A “bariatric standard” intraoperative set up including anaesthetic theatre settings, suitable bed/trolley and operating table, gel padding, wide strapping, table extensions/arm boards, forearm cuff or large blood pressure cuff, ramping device—oxford pillow in theatre or beach chair position—can be adopted on the trolley. Steps for the anaesthetist, difficult airway equipment including a glidescope, ventilator capable of PEEP and pressure modes, a hover mattress, long spinal, regional and vascular needles, ultrasound machine, depth of anaesthesia monitoring, quantitative neuromuscular monitoring and nursing staff trained in both bariatric and CRC operations is needed.

Postoperative considerations

The presence of bariatric service alone does not result in improvement in the postoperative outcome for obese patients with CRC. POPP should address various aspects of postoperative management such as, prophylaxis, treatment, and surveillance. Doses of antibiotics should be adjusted to avoid underdosing. Chemotherapy carries a number of controversies, especially that the American Society of Clinical Oncology Clinical Practice Guidelines recommend dosing according to actual weight, and warn that worse outcomes are seen in underdosing resulting from the unsupported fear of increased toxicity [10]. This may have also contributed to worse local control in rectal cancer for example and thus to the need for a different postoperative surveillance program for earlier detection.

Conclusion

Collaboration between healthcare-workers is one of the pillars of the modern healthcare system. Treatment of obese patients with CRC can be the point where bariatric surgeons and their colorectal colleagues meet. Concepts such as dedicated PPOP and POWR may be the key to allow more access to MICCP. A PPOP serves many purposes and makes the tools required for better MIS experience consistent and readily available, it also helps with the pre-operative and postoperative optimisation for patients and limits the variables seen in management, allowing better understanding of where the pitfalls really are. POWR is widely used in bariatric surgery, and should be further investigated in CRC patients having MICPP and theoretically, it should help overcome some of the anatomical challenges seen in patients undergoing MIS for CRC. With the use of newer technologies such as ICG,
the colorectal surgeon may feel more comfortable performing MICCP. Finally, limiting the challenges seen in obese patients with CRC is complex and thus requires a comprehensive multidisciplinary perioperative approach.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** Informed consent was not required for this study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Obesity and overweight (2019). https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 16 Feb 2018

2. Moussa OM, Erridge S, Chidambaram S, Ziprin P, Darzi A, Purkayastha S (2019) Mortality of the severely obese: a population study. Ann Surg 269(6):1087–1091

3. Bowel Cancer Risk (2018). https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/risk-factors#heading-Five. Accessed 14 June 2018

4. Boodaie BD, Bui AH, Feldman DL, Brodman M, Shamamian P, Kaleya R, Leitman IM (2018) A perioperative care map improves outcomes in patients with morbid obesity undergoing major surgery. Surgery 163(2):450–456. https://doi.org/10.1016/j.surg.2017.09.047

5. Hansen CH, Gögenur M, Madsen MT, Gögenur I (2018) The effect of time from diagnosis to surgery on oncological outcomes in patients undergoing surgery for colon cancer: a systematic review. Eur J Surg Oncol 44(10):1479–1485. https://doi.org/10.1016/j.ejso.2018.06.015

6. Weimann A (2017) Influence of nutritional status on postoperative outcome in patients with colorectal cancer—the emerging role of the microbiome. Innov Surg Sci 3(1):55–64. https://doi.org/10.1515/iss-2017-0039

7. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT (2015) The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol 41(2):186–196

8. Holderbaum M, Casagrande DS, Sussenbach S, Buss C (2018) Effects of very low calorie diets on liver size and weight loss in the preoperative period of bariatric surgery: a systematic review. Surg Obes Relat Dis 14(2):237–244

9. Supe AN, Kulkarni GV, Supe PA (2010) Ergonomics in laparoscopic surgery. J Minim Access Surg 6(2):31–36

10. Lyman GH (2012) Weight-based chemotherapy dosing in obese patients with cancer: back to the future. J Oncol Pract 8(4):e62–e64

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.